CC-90010 is a selective inhibitor of CDK9 (cyclin-dependent kinase 9), a key regulator of transcription in cells. Its primary application lies in oncology research, particularly in the development of therapies for hematological malignancies such as acute myeloid leukemia (AML) and other aggressive cancers. By inhibiting CDK9, CC-90010 disrupts the transcription of short-lived oncoproteins like MCL-1, which cancer cells rely on for survival. This leads to apoptosis (programmed cell death) in malignant cells.

It has shown potential in preclinical and early clinical trials for inducing anti-tumor activity, especially in cancers with high dependence on anti-apoptotic proteins. Due to its targeted mechanism, CC-90010 is being investigated as a monotherapy and in combination with other anti-cancer agents to enhance efficacy and overcome resistance. Its application is mainly focused on patients with relapsed or refractory cancers where conventional treatments have failed.